Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.

NCT06714591 is registered in ClinicalTrials.gov with SystImmune Inc. as lead sponsor.

NCT NCT06714591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06714591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.
Lead sponsor
SystImmune Inc.
Phase
Phase 1
Overall status
Terminated
Start date
December 19, 2024
Completion date
September 16, 2026
Enrollment
52 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory acute myeloid leukemia